508 related articles for article (PubMed ID: 17032413)
1. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
2. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response.
Floreani A; Cazzagon N; Boemo DG; Baldovin T; Baldo V; Egoue J; Antoniazzi S; Minola E
Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):997-1003. PubMed ID: 21915057
[TBL] [Abstract][Full Text] [Related]
3. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
[TBL] [Abstract][Full Text] [Related]
4. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
5. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
6. Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin.
Fabris P; Floreani A; Carlotto A; Baldo V; Bozzola L; Giordani MT; Negro F; Rassu M; Tramarin A; de Lalla F
Aliment Pharmacol Ther; 2005 May; 21(9):1173-8. PubMed ID: 15854181
[TBL] [Abstract][Full Text] [Related]
7. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
Jian Wu Y; Shu Chen L; Gui Qiang W
Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
[TBL] [Abstract][Full Text] [Related]
8. Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.
Amanzada A; Goralczyk A; Moriconi F; Blaschke M; Schaefer IM; van Thiel D; Mihm S; Ramadori G
Dig Dis Sci; 2011 Nov; 56(11):3296-304. PubMed ID: 21994136
[TBL] [Abstract][Full Text] [Related]
9. Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis.
Testino G; Sumberaz A; Ancarani AO; Borro P; Ravetti G; Ansaldi F; Andorno E; Gentile R; Icardi G
Hepatogastroenterology; 2009; 56(90):501-3. PubMed ID: 19579629
[TBL] [Abstract][Full Text] [Related]
10. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.
Hsu CS; Liu CH; Liu CJ; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2009; 14(1):45-54. PubMed ID: 19320236
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
[TBL] [Abstract][Full Text] [Related]
13. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.
AlQaraawi AM; Sanai FM; Al-Husseini H; Albenmousa A; AlSheikh A; Ahmed LR; Hersi A; Al-Otaibi MM; Syed M; Ali SM; Al-hamoudi W; Alswat KA; Abdo AA
Dig Dis Sci; 2011 Apr; 56(4):1222-8. PubMed ID: 20931285
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
16. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
Diago M; Castellano G; García-Samaniego J; Pérez C; Fernández I; Romero M; Iacono OL; García-Monzón C
Gut; 2006 Mar; 55(3):374-9. PubMed ID: 16150856
[TBL] [Abstract][Full Text] [Related]
17. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
[TBL] [Abstract][Full Text] [Related]
18. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
19. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.
Al Ashgar H; Helmy A; Khan MQ; Al Kahtani K; Al Quaiz M; Rezeig M; Kagevi I; Alshehri A; Al Kalbani A; Al Swat K; Dahab S; Elkum N; Al Fadda M
Ann Saudi Med; 2009; 29(1):4-14. PubMed ID: 19139619
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]